公开(公告)号：US20240226150A9

公开(公告)日：2024-07-11

申请号：US18448665

申请日：2023-08-11

申请人： THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  Daegu Gyeongbuk Institute of Science and Technology

发明人： Kiyuk CHANG ,  Daehee HWANG ,  Min-Sik KIM ,  Eunmin KIM ,  Eun Hye PARK ,  Chan Woo KIM

IPC分类号： A61K35/15 ,  A61K39/00 ,  A61P9/04 ,  C07K14/47 ,  C12N5/00 ,  C12N5/0784

CPC分类号： A61K35/15 ,  A61K39/4615 ,  A61K39/4621 ,  A61P9/04 ,  C07K14/4702 ,  C12N5/0018 ,  C12N5/064

摘要： The present disclosure relates to the preparation of citrullinated vimentin antigen-specific immune tolerogenic dendritic cells and a composition for preventing or treating heart failure after myocardial infarction comprising the same. According to the present disclosure, it is confirmed that immune tolerogenic dendritic cells differentiated by treating immature dendritic cells with citrullinated vimentin regulate the expression of immune-related factors and have an excellent therapeutic effect on heart failure caused by myocardial infarction.

公开(公告)号：US20240042025A1

公开(公告)日：2024-02-08

申请号：US18257181

申请日：2021-12-14

申请人： Lior IZHAR ,  Rafi EMMANUEL ,  EmendoBio Inc.

发明人： Lior Izhar ,  Rafi Emmanuel

IPC分类号： A61K39/00 ,  C12N15/11 ,  C12N9/22 ,  C12N15/90

CPC分类号： A61K39/4621 ,  C12N15/11 ,  C12N9/22 ,  C12N15/907 ,  A61K39/4613 ,  A61K39/4612 ,  A61K39/4611 ,  A61K39/4614 ,  C12N2310/20 ,  C12N2800/80

摘要： RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-1538 and compositions, methods, and uses thereof.

公开(公告)号：US20230398215A1

公开(公告)日：2023-12-14

申请号：US18033907

申请日：2021-10-28

申请人： SRI International

发明人： Parijat Bhatnagar

IPC分类号： A61K39/00

CPC分类号： A61K39/4631 ,  A61K39/4613 ,  A61K39/4622 ,  A61K39/464411 ,  A61K39/001112 ,  A61K39/4621 ,  A61K2239/21 ,  A61K2239/22

摘要： An example genetically engineered natural killer (NK) cell comprises an exogenous polynucleotide sequence that includes a receptor element, an actuator element, and an effector element. The receptor element encodes a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain operably linked to a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen binding domain recognizes a surface antigen of a target cell. The actuator element encodes a transcription factor binding site that upregulates synthesis of an effector protein. The effector element encodes the effector protein operably linked to a signal peptide, wherein, in response to the antigen binding domain of the CAR binding to the antigen of the target cell, the engineered NK cell is configured to activate and, to synthesize and secrete the effector protein.

公开(公告)号：US20230398214A1

公开(公告)日：2023-12-14

申请号：US17633294

申请日：2020-08-06

申请人： Yeda Research and Development Co. Ltd. ,  Board of Regents, The University of Texas System

发明人： Yair REISNER ,  Esther BACHAR-LUSTIG ,  Assaf LASK ,  Noga OR-GEVA ,  Rotem GIDRON BUDOVSKY ,  Rakefet SIDLIK MUSKATEL

IPC分类号： A61K39/00 ,  C12N5/0783 ,  A61K31/664 ,  A61P37/06

CPC分类号： A61K39/4622 ,  C12N5/0636 ,  A61K39/4633 ,  A61K39/4614 ,  A61K39/464411 ,  A61K39/46444 ,  A61K39/464838 ,  A61K31/664 ,  A61P37/06 ,  A61K39/464429 ,  A61K39/4621 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2502/1121

摘要： Methods of generating an isolated population of non-graft versus host disease (GVHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, are disclosed. Cells generated by the methods, pharmaceutical compositions and methods of treatment are also disclosed.

公开(公告)号：US20240277772A1

公开(公告)日：2024-08-22

申请号：US18566349

申请日：2022-05-30

申请人： SCM LIFESCIENCE CO., LTD. ,  TERAIMMUNE, LLC

发明人： Sun Uk SONG ,  Si Na KIM ,  Jeong Hyun MOON ,  Jeong Heon YOON ,  Na Ri BYUN

IPC分类号： A61K35/28 ,  A61K8/98 ,  A61K35/17 ,  A61K39/00 ,  A61P17/04 ,  A61P37/06 ,  A61Q19/00 ,  C12N5/0775

CPC分类号： A61K35/28 ,  A61K8/981 ,  A61K35/17 ,  A61K39/4611 ,  A61K39/4621 ,  A61K39/46433 ,  A61P17/04 ,  A61P37/06 ,  A61Q19/00 ,  C12N5/0663 ,  C12N2500/24 ,  C12N2500/38 ,  C12N2501/25

摘要： The present invention relates to: a composition and a kit for preventing, alleviating or treating atopic dermatitis, comprising primed function-enhanced stem cells and regulatory T cells; and a method for preventing, alleviating or treating atopic dermatitis by using same. When function-enhanced stem cells, of the present invention, treated with TNF-α, IFN-γ and IFN-α or TNF-α, IFN-γ, IFN-α and vitamins are treated in combination with regulatory T cells, the imbalance of Th1/Th2 cells of an atopic dermatitis patient can be alleviated and the status of the atopic dermatitis patient can be shifted to Th1, and thus the present invention can be widely used in various fields of prevention, alleviation or treatment of atopic dermatitis.

公开(公告)号：US20240131061A1

公开(公告)日：2024-04-25

申请号：US18448665

申请日：2023-08-10

申请人： THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  Daegu Gyeongbuk Institute of Science and Technology

发明人： Kiyuk CHANG ,  Daehee HWANG ,  Min-Sik KIM ,  Eunmin KIM ,  Eun Hye PARK ,  Chan Woo KIM

IPC分类号： A61K35/15 ,  A61K39/00 ,  A61P9/04 ,  C07K14/47 ,  C12N5/00 ,  C12N5/0784

CPC分类号： A61K35/15 ,  A61K39/4615 ,  A61K39/4621 ,  A61P9/04 ,  C07K14/4702 ,  C12N5/0018 ,  C12N5/064

摘要： The present disclosure relates to the preparation of citrullinated vimentin antigen-specific immune tolerogenic dendritic cells and a composition for preventing or treating heart failure after myocardial infarction comprising the same. According to the present disclosure, it is confirmed that immune tolerogenic dendritic cells differentiated by treating immature dendritic cells with citrullinated vimentin regulate the expression of immune-related factors and have an excellent therapeutic effect on heart failure caused by myocardial infarction.

公开(公告)号：US20240042024A1

公开(公告)日：2024-02-08

申请号：US18254690

申请日：2021-11-23

申请人： David A. HORWITZ ,  GENERAL NANOTHERAPEUTICS LLC

发明人： David A. HORWITZ

IPC分类号： A61K39/00 ,  A61K38/20 ,  A61K38/17 ,  A61K38/18 ,  A61P37/06

CPC分类号： A61K39/4621 ,  A61K39/46434 ,  A61K38/2013 ,  A61K38/1729 ,  A61K38/1841 ,  A61P37/06 ,  A61K2039/5154 ,  A61K2039/577

摘要： A novel nanoparticle platform has been developed that induces and expands multiple populations of suppressive regulatory cells in vivo for the prevention and treatment of immune-mediated disorders. These include autoimmune diseases, graft-versus-host disease, and transplant rejection. The regulatory cells expanded include both CD4+ and CD8+ T cells and NK cells. The nanoparticles function as artificial antigen-presenting cells (aAPC) that target T cells and NK cells and provide them the essential stimulation and cytokines they require for regulatory cell generation, function, and expansion. This is achieved without the use of the toxic immunosuppressive and biological agents now in use.

公开(公告)号：US20230390391A1

公开(公告)日：2023-12-07

申请号：US17759271

申请日：2021-01-22

申请人： REGENTS OF THE UNIVERSITY OF MINNESOTA ,  H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

发明人： Brian BETTS ,  Marco DAVILA

IPC分类号： A61K39/00 ,  C07K16/28 ,  A61P37/06

CPC分类号： A61K39/4621 ,  A61K39/4631 ,  C07K16/2803 ,  C07K16/2866 ,  A61K39/4611 ,  A61P37/06 ,  A61K39/46433 ,  A61K2239/28 ,  C07K2317/622 ,  A61K2239/26

摘要： A bi-specific genetically modified immune cell, comprising a first antigen binding moiety that is specific to CD83 and a second antigen binding moiety that is specific to interleukin 6 receptor (IL-6R). Also provided herein are uses of such bi-specific genetically modified immune cells for suppressing alloreactive donor cells in cell transplantation.

公开(公告)号：US20230372486A1

公开(公告)日：2023-11-23

申请号：US18300981

申请日：2023-04-14

申请人： SENTI BIOSCIENCES, INC.

发明人： Brian Scott GARRISON ,  Michelle Elizabeth HUNG ,  Nicholas FRANKEL

IPC分类号： A61K39/00 ,  C07K16/30 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725

CPC分类号： A61K39/46447 ,  C07K16/3092 ,  A61P35/02 ,  A61K39/4613 ,  A61K39/4611 ,  A61K39/464416 ,  C07K14/70503 ,  C07K14/70521 ,  C07K14/7051 ,  A61K39/4621 ,  A61K39/4631 ,  C07K2317/622 ,  C07K2319/33 ,  A61K2239/28 ,  C07K2319/03 ,  A61K2239/48

摘要： Provided herein are EMCN-specific antigen-binding domains, and chimeric proteins including the EMCN-specific antigen-binding. Also provided herein are cells, nucleic acids, vectors, compositions, and methods directed to proteins including the EMCN-specific antigen-binding domains.

公开(公告)号：US20240358833A1

公开(公告)日：2024-10-31

申请号：US18682764

申请日：2022-08-09

申请人： The Regents of the University of California

发明人： Qizhi TANG ,  Yannick D. MULLER ,  Leonardo M.R. FERREIRA ,  Emilie RONIN ,  Johanna C. WAGNER ,  Yani PENG

IPC分类号： A61K39/00 ,  A61P37/06 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K39/46434 ,  A61K39/4611 ,  A61K39/4621 ,  A61K39/4631 ,  A61P37/06 ,  C07K14/7051 ,  C07K16/2833 ,  C12N5/0637 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/622 ,  C12N2510/00

摘要： The present disclosure relates to chimeric-antigen-receptor regulatory T cells (CAR-Tregs) that include an exogenous nucleic acid encoding a chimeric antigen receptor (CAR) comprising the complementarity determining regions (CDRs) of a human anti-HLA-A2 antibody grafted onto an antibody scaffold, a hinge domain, a transmembrane domain; and an intracellular domain, where the CAR-Treg expresses the CAR on the cell surface. Vectors and methods of making and using such CAR-Tregs are disclosed as well.